Medical Condition News

RSS

Dobkin technique delays brain damage in heart attack victims

After a heart attack and the victim stops breathing, a process of irreversible brain damage starts to occur within 3 to 4 minutes. Or does it?

27 Oct 2010

Human haptoglobin gene mutation increases risk of diabetic complications

Type 1 diabetes (T1D), formerly known as juvenile diabetes, is a multifactorial disease of complex etiology characterized by the autoimmune destruction of pancreatic beta cells. In addition to genetic susceptibility, it is generally accepted that environmental factors play important roles in triggering disease, with virus infection having perhaps the strongest association.

27 Oct 2010

Myriad signs agreement with Abbott for BRACAnalysis test

Myriad Genetics, Inc. today announced that it has signed an agreement with Abbott Laboratories, a global health care company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III multi-center, multi-national clinical study of a novel drug candidate for the treatment of metastatic breast cancer.

27 Oct 2010

Brain adapts to vision loss by increasing speed of tactile perception

People who are blind from birth are able to detect tactile information faster than people with normal vision, according to a study in the Oct. 27 issue of The Journal of Neuroscience.

27 Oct 2010

New portable scanner for breast cancer diagnosis

Professor Zhipeng Wu has invented a portable scanner based on radio frequency technology, which is able to show in a second the presence of tumours malignant and benign in the breast on a computer.

From The University of Manchester 27 Oct 2010

Lifestyle intervention programs result in significant weight loss for overweight and severly obese adults

Lifestyle interventions, including physical activity and structured weight loss programs, can result in significant weight loss for overweight, obese and severely obese adults, according to two reports that were posted online October 9 by JAMA. The studies and accompanying editorials were made available early online to coincide with the presentation of these papers at the 28th Annual Scientific Meeting of the Obesity Society. The articles appear in the October 27 print issue of JAMA.

27 Oct 2010

IMRT reduces gastrointestinal complications in prostate cancer patients

Prostate cancer patients who receive intensity modulated radiation therapy (IMRT) are less apt to suffer serious gastrointestinal complications following their treatment than those who receive three-dimensional conformal radiotherapy (CRT), according to new research from the University of Pennsylvania School of Medicine.

27 Oct 2010

Pain could predict survival of liver cancer patients

Understanding the role of pain hepatocellular carcinoma (HCC) or liver cancer is critical since pain has adverse effects on quality of life and could be a predictor of survival, according to research reported in The Journal of Pain, published by the American Pain Society, www.ampainsoc.org.

27 Oct 2010

Addition of ECC probe to SOLiD System's chemistry achieves greater than 99.99% single-read accuracy

Life Technologies Corporation a provider of innovative life science solutions, today announced that it has established a new standard in accuracy for next generation sequencing. By adding an Exact Call Chemistry (ECC) proprietary probe to its market leading ligation chemistry, the company has demonstrated greater than 99.99% average single-read accuracy.

27 Oct 2010

Adherence to lifestyle recommendations reduces risk of colorectal cancer by 23%

Almost a quarter of colorectal (bowel) cancer cases could be prevented if people followed healthy lifestyle advice in five areas including diet and exercise, says a new study published on bmj.com today.

27 Oct 2010

Bayer launches unique fitness program for hemophilia A children

Bayer HealthCare is introducing a fitness program to help children ages 7-12 and young adults ages 13-16 with hemophilia A live active lives. "Living Fit! A Joint Effort" is a unique strength training, fitness and wellness program created to increase awareness of the importance of exercise and nutrition among this population and their caregivers.

27 Oct 2010

Columbia University researchers to use IBM's streaming analytics to detect complications in brain injury

IBM today announced a new project in which researchers at Columbia University Medical Center will utilize IBM's streaming analytics technology to potentially detect severe complications in brain injured patients up to 48 hours earlier than traditional methods.

27 Oct 2010

Oramed to present data on oral insulin formulation for Type II diabetes at Annual Meeting in Bethesda

Oramed Pharmaceuticals Inc. a developer of oral drug delivery systems, announced today that its work entitled "Extended exposure to an oral insulin formulation yields decreased insulin secretion in Type II diabetes subjects," will be presented at the Tenth Annual Meeting of the Diabetes Technology Society, to be held in Bethesda, Maryland this November.

27 Oct 2010

Study finds association between KRAS p.G13D mutations and cetuximab treatment in colorectal cancer

Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations, according to a study in the October 27 issue of JAMA.

27 Oct 2010

Study finds anti-obesity drug reduces brain’s response to appetizing foods

Scientists have revealed that an anti-obesity drug changes the way the brain responds to appetising, high-calorie foods in obese individuals. This insight may aid the development of new anti-obesity drugs which reduce the activity in the regions of the brain stimulated by the sight of tasty foods.

27 Oct 2010

Oncolytics presents REO 013 clinical trial data for colorectal cancer at International Symposium in Spain

Oncolytics Biotech Inc. announced today that interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases was presented at the International Symposium on Cytotoxic T-lymphocytes (CTL) and Immunostimulation being held in Pamplona, Spain.

27 Oct 2010

CYP2C19 gene variant can increase risk of cardiovascular events in patients treated with clopidogrel

An analysis of data from previously published studies indicates that use of the antiplatelet drug clopidogrel for patients who have common genetic variants of a certain gene and are undergoing a procedure such as coronary stent placement have an associated increased risk for major adverse cardiovascular events, particularly development of blood clots in stents, according to a study in the October 27 issue of JAMA.

27 Oct 2010

Sirius receives U.S. patent for using SNP in Protein C gene

Sirius Genomics, a developer of companion diagnostics, announced today that U.S. Patent 7,820,376 entitled "Protein C Polymorphisms" has been issued by the United States Patent and Trademark Office. The patent relates to a novel use of a Single Nucleotide Polymorphism (SNP) located in the Protein C gene.

27 Oct 2010

Pledge to reduce antipsychotic use in dementia sufferers

A new coalition of 44 organizations called the Dementia Action Alliance, has called for a cut in the use of anti-psychotic drugs for patients with dementia. The coalition includes Alzheimer's Research Trust, Alzheimer's Society, BUPA, Dementia UK, the Royal College of Psychiatrists, Royal College of General Practitioners and Stroke Association.

26 Oct 2010

Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals reported today the randomization of the last patient in its short-term study component of its Phase 3 registration program of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

26 Oct 2010

Medical Condition News

Dobkin technique delays brain damage in heart attack victims

Human haptoglobin gene mutation increases risk of diabetic complications

Myriad signs agreement with Abbott for BRACAnalysis test

Brain adapts to vision loss by increasing speed of tactile perception

New portable scanner for breast cancer diagnosis

Lifestyle intervention programs result in significant weight loss for overweight and severly obese adults

IMRT reduces gastrointestinal complications in prostate cancer patients

Pain could predict survival of liver cancer patients

Addition of ECC probe to SOLiD System's chemistry achieves greater than 99.99% single-read accuracy

Adherence to lifestyle recommendations reduces risk of colorectal cancer by 23%

Bayer launches unique fitness program for hemophilia A children

Columbia University researchers to use IBM's streaming analytics to detect complications in brain injury

Oramed to present data on oral insulin formulation for Type II diabetes at Annual Meeting in Bethesda

Study finds association between KRAS p.G13D mutations and cetuximab treatment in colorectal cancer

Study finds anti-obesity drug reduces brain’s response to appetizing foods

Oncolytics presents REO 013 clinical trial data for colorectal cancer at International Symposium in Spain

CYP2C19 gene variant can increase risk of cardiovascular events in patients treated with clopidogrel

Sirius receives U.S. patent for using SNP in Protein C gene

Pledge to reduce antipsychotic use in dementia sufferers

Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News